Skip to Main Content
Contribute Try STAT+ Today

Blueprint Medicines is partnering with Roche to develop and market a cancer drug near approval for use in patients with tumors that test positive for a specific genetic mutation.

The drug at the center of the deal is a pill called pralsetinib, created and developed by the Cambridge, Mass-based biotech to target solid tumors with alterations to a gene called RET. Blueprint has already submitted pralsetinib to the Food and Drug Administration and European regulators seeking approval to treat patients with RET-driven, non-small cell lung cancer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.